Previous 10 | Next 10 |
home / stock / dtcff / dtcff news
Vancouver, British Columbia--(Newsfile Corp. - May 17, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug deliver...
Defence Therapeutics (OTCPK:DTCFF) said the United States Patent and Trademark Office (USPTO) had granted a patent number to its vaccine platform technology for the treatment and prevention of a wide range of cancers and infectious diseases, including COVID-19. The patent number '717 wil...
Vancouver, British Columbia--(Newsfile Corp. - April 7, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company primarily focused on the development of novel vaccines and drug delivery technologies, is ple...
Vancouver, British Columbia--(Newsfile Corp. - March 22, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF)(" Defence " or the " Company "), a Canadian biotech company actively working on accelerating scientific discoveries and products development against cancer, is ple...
Vancouver, British Columbia--(Newsfile Corp. - February 28, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a pre-clinical biotechnology company developing various products for the immune-oncology space, is pleased to announce the pub...
Vancouver, British Columbia--(Newsfile Corp. - February 16, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a pre-clinical biotechnology company developing various products for the immune-oncology space, is pleased to announce the est...
Vancouver, British Columbia--(Newsfile Corp. - January 26, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a pre-clinical biotechnology company developing various immune-oncology products, is pleased to announce the development of Acc...
Vancouver, British Columbia--(Newsfile Corp. - January 10, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a pre-clinical biotechnology company developing various immune-oncology products, is pleased to announce the start of its final...
Vancouver, British Columbia--(Newsfile Corp. - December 13, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a biotechnology company focused on the development of vaccines and therapeutics against cancer and infectious diseases, is ple...
Vancouver, British Columbia--(Newsfile Corp. - November 30, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), is a publicly-traded biotechnology company working on engineering the next generation vaccines, Antibody Drug Conjugates, ADC ...
News, Short Squeeze, Breakout and More Instantly...
Defence Therapeutics Inc Cl A Company Name:
DTCFF Stock Symbol:
OTCMKTS Market:
Defence Therapeutics Inc Cl A Website:
Vancouver, British Columbia--(Newsfile Corp. - July 8, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that it...
Vancouver, British Columbia--(Newsfile Corp. - June 28, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is please to announce that De...
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce th...